8-K: Tempest Therapeutics Reports Q3 2026 Results, Secures Capital

Tempest Therapeutics announced third quarter 2026 financial results, highlighting progress in its in vivo CAR-T platforms, securing new capital, and strengthening its board.

Summary

• Tempest Therapeutics reported financial results for the quarter ended September 30, 2026.
• The company exercised an option to exclusively license Senlang's CD7-targeted lentiviral vector platform and associated in vivo CAR-T candidates, including TPST-4903, a BCMA/GPRC5D dual-targeting candidate in Phase 1 for relapsed/refractory multiple myeloma.
• A new pipeline candidate, TPST-4003, a CD19/BCMA dual-targeting in vivo CAR-T, was unveiled.
• An investigator-initiated trial for TPST-4003 in myasthenia gravis or multiple sclerosis is expected to begin in Q4 2026 in China.
• The company secured up to $50.0 million through an equity line of credit with Lincoln Park Capital and approximately $2.5 million in gross proceeds from a private placement.
• Tempest ended Q3 2026 with $0.9 million in cash and cash equivalents, down from $7.7 million at the end of 2025.
• The company reported a net loss of $3.6 million ($0.21 per share) for Q3 2026, compared to a net loss of $3.5 million ($0.79 per share) for Q3 2025.
• For the nine months ended September 30, 2026, the net loss was $36.6 million ($2.54 per share), compared to $22.2 million ($5.71 per share) for the same period in 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a cautiously negative score due to significant cash burn, a going concern warning, and a substantial net loss, despite strategic advancements and capital raises.

Positives

• Exclusive license secured for Senlang's CD7-targeted lentiviral vector platform and in vivo CAR-T candidates, including TPST-4903.
• Advancement of lead BCMA/GPRC5D candidate TPST-4903 in Phase 1 study for relapsed or refractory multiple myeloma.
• Unveiled next-generation in vivo CAR-T pipeline candidate, TPST-4003.
• Secured access to up to $50.0 million via an equity line of credit with Lincoln Park Capital.
• Completed a private placement raising approximately $2.5 million in gross proceeds.
• Strengthened the Board of Directors with the appointments of Nancy Freda-Smith and John W. Frederick.

Negatives

• Ended Q3 2026 with $0.9 million in cash and cash equivalents, a significant decrease from $7.7 million at the end of 2025.
• The company's existing cash is expected to fund operating expenses for less than 12 months.
• There is substantial doubt about the company's ability to continue as a going concern.
• Net loss for Q3 2026 was $3.6 million, a slight increase from $3.5 million in Q3 2025.
• Net loss for the nine months ended September 30, 2026, was $36.6 million, a significant increase from $22.2 million in the prior year period.
• Research and development expenses decreased significantly from $12.1 million to $2.1 million for the nine-month period, indicating a potential slowdown in R&D activity.
• Acquired in-process research and development expenses of $22.2 million for the nine months ended September 30, 2026.

Risks

• The company's existing cash and cash equivalents are expected to fund its projected operating expense requirements for less than 12 months, raising substantial doubt about its ability to continue as a going concern.
• The need for additional capital to fund planned programs and operations.
• Unexpected safety or efficacy data observed during preclinical or clinical trials.
• The possibility that results from prior clinical trials and preclinical studies may not necessarily be predictive of future results.
• Clinical trial site activation or enrollment rates that are lower than expected.
• Loss of key personnel.
• Changes in expected or existing competition.
• Changes in the regulatory environment.

Future Outlook

The company's existing cash is expected to fund its operating expenses for less than 12 months, and there is substantial doubt about its ability to continue as a going concern. The company has secured access to additional capital through an equity line of credit and a private placement to support its development priorities.

Management Comments

• "The third quarter marked a period of meaningful progress in the advancement of two next-generation in vivo CAR-T platforms with the potential to transform treatment across multiple diseases," said Matt Angel, Ph.D., president and chief executive officer of Tempest.
• "We made important strides in expanding our pipeline and strengthening our position in the rapidly evolving in vivo CAR-T landscape through our strategic collaboration with Senlang by obtaining exclusive license rights to our clinical-stage BCMA/GPRC5D in vivo CAR-T candidate TPST-4903, while securing access to additional capital to support our development priorities."
• "We also welcomed two accomplished independent directors to our Board, bringing valuable corporate governance and capital markets expertise as we navigate our next phase of growth."
• "Together, these achievements reinforce our commitment to advancing our pipeline, executing on our strategic priorities and unlocking the broad therapeutic potential of in vivo CAR-T therapies for patients."

Industry Context

StockSavvy.ai notes that Tempest Therapeutics is operating in the highly competitive and capital-intensive clinical-stage biotechnology sector, specifically focusing on in vivo CAR-T therapies. This field is characterized by rapid innovation, significant R&D investment, and a high risk of clinical trial failure, but also offers the potential for transformative treatments. The company's strategic moves, including licensing and capital raises, are typical for companies at this stage aiming to advance their pipeline.

Management Changes

Stakeholder Impact

• Shareholders may experience dilution due to potential sales of common stock under the Lincoln Park purchase agreement and the exercise of outstanding warrants.
• The going concern warning may impact investor confidence and the company's ability to secure future financing.
• Employees may face uncertainty due to the company's financial position and the need for continued capital.

Next Steps

• Initial data from the Phase 1 study of TPST-4903 is expected to be presented at an upcoming scientific conference.
• An investigator-initiated trial in China evaluating TPST-4003 in approximately 10 patients with myasthenia gravis or multiple sclerosis is expected to begin in the fourth quarter of 2026.
• The company will continue to advance its pipeline of in vivo CAR-T product candidates.

Key Dates

Recommendation

The company has made strategic advancements in its pipeline and secured necessary capital, which are positive developments. However, the significant net losses, dwindling cash reserves, and the explicit 'going concern' warning present substantial risks that temper a more aggressive recommendation. A 'hold' position allows investors to monitor the progress of clinical trials and the company's ability to manage its cash burn and secure further funding.

Keywords

in vivo CAR-T, biotechnology, cancer, autoimmune disease, TPST-4903, TPST-4003, multiple myeloma, clinical-stage